The acquisition of successful small- to medium-sized pharmaceutical companies by a larger market player and the additional funds and resources this provides can really propel research forward. Equally, it is one of many strategies that bigger companies use to reduce some of the financial risk associated with carrying out their own in-house research.
Whatever the motivation, it is important that the potential drugs and commercial processes have adequate protection. Without sufficient and demonstrable market exclusivity, interest in an M&A discussion may be hard to come by. So if you are a small- to mid-sized pharmaceutical company with a potential future interest in joining forces with a larger undertaking, read on as we examine a selection of ways to get your proverbial patent ducks in a row before taking further steps.
This content is restricted to members. To view this content please register or login below to view this content.